307 related articles for article (PubMed ID: 30134343)
1. Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.
Sungu N; Yildirim M; Desdicioglu R; Başaran Aydoğdu Ö; Kiliçarslan A; Tatli Doğan H; Kiliç Yazgan A; Akyol M; Erdoğan F
Int J Gynecol Pathol; 2019 Sep; 38(5):404-413. PubMed ID: 30134343
[TBL] [Abstract][Full Text] [Related]
2. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
4. Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.
Hecking T; Thiesler T; Halbe J; Otten L; Recker F; Gevensleben H; Müller T; Schiller C; Egger EK; Fimmers R; Stope MB; Kristiansen G; Mustea A
Anticancer Res; 2022 Mar; 42(3):1367-1376. PubMed ID: 35220229
[TBL] [Abstract][Full Text] [Related]
5. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
Zheng B; Ren T; Huang Y; Sun K; Wang S; Bao X; Liu K; Guo W
J Hematol Oncol; 2018 Feb; 11(1):16. PubMed ID: 29409495
[TBL] [Abstract][Full Text] [Related]
6. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy.
Tanaka K; Miyata H; Sugimura K; Kanemura T; Hamada-Uematsu M; Mizote Y; Yamasaki M; Wada H; Nakajima K; Takiguchi S; Mori M; Doki Y; Tahara H
Cancer Sci; 2016 Jun; 107(6):726-33. PubMed ID: 27015293
[TBL] [Abstract][Full Text] [Related]
7. Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.
Kir G; Soylemez T; Olgun ZC; Aydin A; McCluggage WG
Virchows Arch; 2020 Dec; 477(6):845-856. PubMed ID: 32594230
[TBL] [Abstract][Full Text] [Related]
8. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
[TBL] [Abstract][Full Text] [Related]
9. Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization.
Chang H; Hong JH; Lee JK; Cho HW; Ouh YT; Min KJ; So KA
J Gynecol Oncol; 2018 May; 29(3):e27. PubMed ID: 29400020
[TBL] [Abstract][Full Text] [Related]
10. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
[TBL] [Abstract][Full Text] [Related]
11. Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency.
Li Z; Joehlin-Price AS; Rhoades J; Ayoola-Adeola M; Miller K; Parwani AV; Backes FJ; Felix AS; Suarez AA
Int J Gynecol Cancer; 2018 Jan; 28(1):59-68. PubMed ID: 29053481
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
[TBL] [Abstract][Full Text] [Related]
13. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study.
Wahba MG; Soliman SS; Salama ME; Nasr S; Al Shereef ZAE
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1441-1450. PubMed ID: 38680006
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
16. Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.
Takada K; Toyokawa G; Azuma K; Takamori S; Jogo T; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
In Vivo; 2018; 32(6):1541-1550. PubMed ID: 30348714
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of PD-L1 and PD-L2 in breast cancer.
Baptista MZ; Sarian LO; Derchain SF; Pinto GA; Vassallo J
Hum Pathol; 2016 Jan; 47(1):78-84. PubMed ID: 26541326
[TBL] [Abstract][Full Text] [Related]
18. A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma.
Steuer CE; Griffith CC; Nannapaneni S; Patel MR; Liu Y; Magliocca KR; El-Deiry MW; Cohen C; Owonikoko TK; Shin DM; Chen ZG; Saba NF
Mol Cancer Ther; 2018 Mar; 17(3):710-716. PubMed ID: 29440293
[TBL] [Abstract][Full Text] [Related]
19. Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer.
Mo Z; Liu J; Zhang Q; Chen Z; Mei J; Liu L; Yang S; Li H; Zhou L; You Z
Oncol Lett; 2016 Aug; 12(2):944-950. PubMed ID: 27446374
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer.
Hong JH; Cho HW; Ouh YT; Lee JK; Chun Y
J Gynecol Oncol; 2023 Mar; 34(2):e18. PubMed ID: 36509464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]